Pneumonia News and Research

Latest Pneumonia News and Research

IDSA calls for global commitment to develop 10 new antibiotics by 2020

As the deaths and suffering caused by antibiotic-resistant bacterial infections continue to rise around the world, the Infectious Diseases Society of America (IDSA) is urging a global commitment to develop 10 new antibiotics by 2020, known as the 10 x '20 initiative, to address this public health crisis and safeguard patients' health.

17 Mar 2010

Today's Opinions and Editorials

After a year of national debate, a handful of House Democrats who oppose abortion may be the ones to decide whether health care reform goes forward or not. ... We are puzzled and dismayed that these legislators are willing to waste that opportunity because they say the onerous anti-abortion provisions in the Senate's bill are still not onerous enough (3/14).

15 Mar 2010

More focus on reaching MDGs needed, development officials say

During a conference in London Thursday, development officials urged world leaders to "accelerate efforts to meet the Millennium Development Goals (MDGs) by 2015 and [said] rich countries must make good on promises to boost aid to poorer nations," Reuters AlertNet reports.

15 Mar 2010

GAVI Alliance reaches agreement with drugmakers on reduced-price pneumococcal vaccines

Several drugmakers have reached an agreement "to supply up to 200 million doses a year of cut-price pneumococcal vaccines to developing nations," according to GAVI Alliance, Reuters reports.

15 Mar 2010

TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints

TaiGen Biotechnology Co., Ltd. announced today the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability.

12 Mar 2010

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

On March 10-11, 2010, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) -- including the Pulmonary-Allergy Drugs and the Drug Safety and Risk Management Advisory Committees -- discussed the design of post-marketing safety studies for long-acting beta-agonist (LABA)-containing products in the U.S., including SYMBICORT® (budesonide/formoterol fumarate dihydrate).

12 Mar 2010

Children with chronic illness more likely to develop H1N1 influenza: Study

As critical care professionals develop a better understanding of the progression of H1N1, they are becoming better prepared to treat children with severe cases, according to a new study that will be published in the March issue of Pediatric Critical Care Medicine (PCCM).

12 Mar 2010

WHO welcomes Gates Foundation support in advancing global vaccine efforts

WHO welcomes the Bill & Melinda Gates Foundation pledge of US$ 10 billion over the next ten years to accelerate global vaccine efforts.

12 Mar 2010

HTDS receives Registration Certificate for MEVAC-Vari vaccine in Guatemala

Hard to Treat Diseases and its subsidiary Mellow Hope announce that the company received Registration Certificate for its MEVAC-Vari vaccine in Guatemala.

12 Mar 2010

FDA provides guidance on Restanza clinical program in treatment of CABP

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that the U.S. Food and Drug Administration has provided guidance on the clinical program required to assess the approvability of Restanza™ (cethromycin), a novel oral once-a-day antibiotic, in the treatment of outpatient community acquired bacterial pneumonia (CABP) as well as biodefense indications including anthrax, plague and tularemia.

11 Mar 2010

Advanced Life Sciences Holdings reports decrease in net loss for full-year 2009

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2009.

11 Mar 2010

Cempra Pharmaceuticals completes Phase 1 clinical trials of CEM-101 macrolide

Cempra Pharmaceuticals today announced the successful completion of Phase 1 clinical trials of its oral formulation of CEM-101, which showed good tolerability in those studies. The company also announced plans to submit an IND to the FDA to begin a Phase 1 study with the company's intravenous formulation of CEM-101 in mid-2010.

10 Mar 2010

Inadvertent exposure of hospital housekeepers to drug-resistant "Superbugs" may lead to hospital-infection epidemic

One cause of the rampant international hospital-infection epidemic may be the "inadvertent exposure" of hospital housekeepers and transporters to antibiotic-resistant "Superbugs" such as MRSA, says TeleTracking Technologies CEO Anthony Sanzo.

10 Mar 2010

Winners of NMSIS scholarship award

Two winners have been selected for the Promising New Investigators Travel Scholarship Awards given annually by the Neuroleptic Malignant Syndrome Information Service (NMSIS).

10 Mar 2010

University of Michigan Health System evaluates factors that can reduce hospital deaths

Admission to a hospital when most of the beds are already full can be deadly for patients, according to a new University of Michigan Health System study showing high occupancy increases the risk of dying in the hospital by 5.6 percent.

9 Mar 2010

USF study: HHV-6 causes permanent infection by inserting its DNA into human chromosomes

Human herpesvirus 6 (HHV-6) infects nearly 100 percent of humans in early childhood, and the infection then lasts for the rest of a person's life. Now, a team led by Peter Medveczky, MD, a professor in the Department of Molecular Medicine at the University of South Florida, has discovered that in some individuals, HHV-6 causes such a permanent infection by inserting or "integrating" its DNA into human chromosomes.

9 Mar 2010

PDVI launches new web site for tracking dengue fever epidemics

PDVI, a program of the International Vaccine Institute funded by the Bill & Melinda Gates Foundation, announces today the launch of http://www.denguewatch.org, a news hub for tracking dengue fever epidemics worldwide.

9 Mar 2010

Presentation of results from open-label extension study of Xenazine

Lundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine- (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant reduction in chorea score (p< 0.0001) as measured using the Unified Huntington's Disease Rating Scale (UHDRS) compared with baseline.

6 Mar 2010

Lancet World Report examines GAVI's funding gap

Lancet World Report examines the challenges ahead for the GAVI Alliance, which after a decade of "steadily increasing financing" is now "facing a funding shortfall for the next decade that could hamper the roll-out of new vaccines." GAVI leaders attribute the funding challenges to the global economic crisis, which has kept government aid budgets from increasing, according to the Lancet.

6 Mar 2010

Study finds Pfizer's pneumonia, meningitis vaccine protects against recurrent pneumonia in HIV patients

Pfizer's Prevnar 7 vaccine, which protects against pneumonia and meningitis, has been shown to reduce the risk of recurrent pneumococcal infection in patients living with HIV in Malawi, according to a study published Thursday in the New England Journal of Medicine, Reuters reports.

5 Mar 2010